{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-257937","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2022-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.041654+00:00","generated_at":"2026-06-23T05:24:50.860830+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M","bullets":["Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.","ETX-155 60mg single-dose exposures in Phase 1 PK trial consistent with prior trials; low PSE exposures within previously reported variability.","Company to evaluate 75mg repeat dose in ongoing Phase 1 PK trial; final results expected Q4 2022.","Phase 2a MDD trial to initiate Q1 2023; topline data mid-2024. PSE trial not reinitiated; FOS development continues.","Kv7 program: two pre-candidates scaling up for IND-enabling studies Q1 2023; Phase 1 studies H1 2024. GAD program discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-257937","json":"https://secwatch.observer/filing/0001193125-22-257937.json","markdown":"https://secwatch.observer/filing/0001193125-22-257937.md","text":"https://secwatch.observer/filing/0001193125-22-257937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/0001193125-22-257937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/d401397d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:24:50.860830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}